Drug products: Calmuril, Canoderm®, Caress®, Fenuril®, Karbamid ACO, Karbamid Evolan, Karbamid i Decubal® kräm APL, Karbamid i Essex B kräm APL, Karbamid i Essex kräm APL, Karbamid i Essex lotion APL, Karbamid i Locobase® kräm APL, Karbamid i Locobase® lotion APL, Karbasal, Karbiderm, Monilen
ATC code: D02AE01
Substances: urea, urea (C-13), urea (C-14)
The main indication of carbamide preparations is moisturizing treatment of dry skin. Controlled studies on differences between men and women on efficacy, safety, and pharmacokinetics for carbamide are lacking.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of carbamide have been found.
No studies with a clinically relevant sex analysis regarding the effect of carbamide have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of carbamide have been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men .
Date of litterature search: 2014-09-01
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson